Vaccine (mRNA vaccine) · Immune activation, directed at orthopoxvirus VP37 (F13L) · developed by BioNTech
BNT166a is an investigational vaccine given by intramuscular injection into the deltoid muscle. It is studied for prevention of mpox, smallpox and orthopoxvirus infection.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT07379580 | Phase 2 | Mpox (Monkeypox) | Recruiting | BNTX |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Mpox (Monkeypox)Orthopoxvirus InfectionSmallpox
Updated Nov 8, 2026. Something wrong or missing? Report it on the BNTX page.
See BNTX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
BNTX catalysts and pipeline →